Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2016, Article ID 7275860, 3 pages
http://dx.doi.org/10.1155/2016/7275860
Case Report

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis

1Department of Internal Medicine, Medical College, Umm-Al Qura University, Makkah, Saudi Arabia
2Department of Internal Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
3Alzaidi Chair of Research in Rheumatic Disease, Umm-Al Qura University, Makkah, Saudi Arabia

Received 16 December 2015; Accepted 8 February 2016

Academic Editor: Mario Salazar-Paramo

Copyright © 2016 Neveen Awad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. B. Jones, J. W. C. Tervaert, T. Hauser et al., “Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis,” The New England Journal of Medicine, vol. 363, no. 3, pp. 211–220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. J. H. Stone, P. A. Merkel, R. Spiera et al., “Rituximab versus cyclophosphamide for ANCA-associated vasculitis,” The New England Journal of Medicine, vol. 363, no. 3, pp. 221–232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. U. Specks, P. A. Merkel, P. Seo et al., “Efficacy of remission-induction regimens for ANCA-associated vasculitis,” The New England Journal of Medicine, vol. 369, no. 5, pp. 417–427, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Guillevin, C. Pagnoux, A. Karras et al., “Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis,” The New England Journal of Medicine, vol. 371, no. 19, pp. 1771–1780, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Mukhtyar, R. Lee, D. Brown et al., “Modification and validation of the Birmingham vasculitis activity score (version 3),” Annals of the Rheumatic Diseases, vol. 68, no. 12, pp. 1827–1832, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. B. Cohen, P. Emery, M. W. Greenwald et al., “Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks,” Arthritis & Rheumatism, vol. 54, no. 9, pp. 2793–2806, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. E. P. Rhee, K. A. Laliberte, and J. L. Niles, “Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1394–1400, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Stasi, E. Stipa, G. Del Poeta, S. Amadori, A. C. Newland, and D. Provan, “Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab,” Rheumatology, vol. 45, no. 11, pp. 1432–1436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Moog, M. Probst, C. Kuechle, C. Hauser, U. Heemann, and K. Thuermel, “Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients,” Scandinavian Journal of Rheumatology, vol. 43, no. 6, pp. 519–523, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. T. F. Hiemstra, M. Walsh, A. Mahr et al., “Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial,” The Journal of the American Medical Association, vol. 304, no. 21, pp. 2381–2388, 2010. View at Publisher · View at Google Scholar · View at Scopus